Overall, this study develops a novel small molecular engineered from ezetimibe for treating lethal prostate cancer in an AR‐independent manner and provides mechanistic insights into its action by triggering PLK1‐TP53‐SAT1 axis‐mediated ferroptosis in lethal PCa models independent of the AR signaling pathway. Here, AR is linked to prostate carcinoma.